Managing multiple cardiovascular risk factors

Journal of Family Practice

Volumn 57, Issue 3, 2008, Pages

  Blank, Roy C ^a   Brunton, Stephen ^b,c  

^a Southern Piedmont   (United States)

^b Medicine Residency Program   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; COLESEVELAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; NICOTINIC ACID; OMEGA 3 FATTY ACID; ROSIGLITAZONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TOBACCO SMOKE; TRIACYLGLYCEROL; VARENICLINE;

ABDOMINAL OBESITY; AEROBIC EXERCISE; ANGINA PECTORIS; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRESSLER SYNDROME; DRUG TOLERABILITY; DYSLIPIDEMIA; ENVIRONMENTAL EXPOSURE; GARDENING; GENERAL PRACTICE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HEART MUSCLE REVASCULARIZATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MEDICAL SOCIETY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE; TOBACCO DEPENDENCE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WALKING; WEIGHT CONTROL; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 40749106934     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Ezzati M, Lopez AD, Rodgers A, et al; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
2. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10:163-170.
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
4. Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901-2907.
5. American Heart Association. Risk Factors and Coronary Heart Disease. http://www.americanheart.org/presenter.jhtml?identifier=500. Accessed Jan 10, 2008.
6. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
7. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ. 2001;322:977-980.
8. Yusuf S, Hawken S, Ounpuu S, et al, on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
9. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Endorsed by the American College of Cardiology Foundation. Circulation. 2004;110:2952-2967.
10. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; doi: 10.1136/bmj.39385.413113. 25 (published online Nov. 15 2007).
11. Murphy MH, Nevill AM, Murtagh EM, et al. The effect of walking on fitness, fatness and resting blood pressure: a meta-analysis of randomised, controlled trials. Prev Med. 2007;44:377-385.
12. Chobanian AV, Bakris GL, Black HR, et al, for the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
13. Julius S, Kjeldsen SE, Brunner H, et al. VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544-548.
14. Julius S, Kjeldsen SE, Weber M, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
15. Cushman WC, Ford CE, Cutler JA, et al, for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
17. Grundy SM, Cleeman JI, Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program. Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110;227-239.
18. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
20. Sever PS, Dahlof B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
21. Colhoun HM, Betteridge DJ, Durrington PN, et al, for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
23. Sever P, Dahlöf B, Poulter N, et al, for the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982-2988.
24. Gaede P, Vedel P, Larson N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
25. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
26. LaRosa JC, Grundy SM, Waters DD, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
27. Kostis JB, Breazno A, LaRosa JC, et al. The benefits of intensive lipid lowering in patients with stable CHD and systolic blood pressure above or below 140 mm Hg: a post-hoc analysis of the TNT study. J Clin Hypertens. 2006;8:455 (abstract).
28. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive an lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
29. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847-852.
30. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. Med Gen Med. 2007;9:58.
31. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.